The humanized anti-glycoprotein Ib monoclonal antibody h6B4-Fab is a potent and safe antithrombotic in a high shear arterial thrombosis model in baboons

Summary

The Fab-fragment of 6B4, a murine monoclonal antibody targeting the human platelet glycoprotein (GP) Ibα and blocking the binding of von Willebrand factor (VWF), is a powerful antithrombotic. In baboons, this was without side effects such as bleeding or thrombocytopenia. Recently, we developed a fully recombinant and humanized version of 6B4-Fab-fragment, h6B4-Fab, which maintains its inhibitory capacities in vitro and ex vivo after injection in baboons. We here investigated the antithrombotic properties, the effect on bleeding time and blood loss and initial pharmacokinetics of h6B4-Fab in baboons. The antithrombotic effect of h6B4-Fab on acute platelet-mediated thrombosis was studied in baboons where thrombus formation is induced at an injured and stenosed site of the femoral artery, allowing for cyclic flow reductions (CFRs) which are measured on an extracorporeal femoral arteriovenous shunt. Injection of 0.5 mg/kg h6B4-Fab significantly reduced the CFRs by 80%, whereas two extra injections, resulting in cumulative doses of 1.5 and 2.5 mg/kg, completely inhibited the CFRs. Platelet receptor occupancy, plasma concentrations and effects ex vivo were consistent with what was previously observed. Finally, minimal effects on bleeding time and blood loss, no spontaneous bleeding and no thrombocytopenia were observed. We therefore conclude that h6B4-Fab maintains the antithrombotic capacities of the murine 6B4-Fab, without causing side effects and therefore can be used for further development.

Keywords

Antithrombotic - glycoprotein Ib - humanized antibody - platelet adhesion - thrombosis

• References

• 1 Ruggeri ZM. Mechanisms initiating platelet thrombus formation. Thromb Haemost 1997; 78: 611-616.
• 2 Cauwenberghs N, Vanhoorelbeke K, Vauterin S. et al. Epitope mapping of inhibitory antibodies against platelet glycoprotein Ibalpha reveals interaction between the leucine-rich repeat N-terminal and C-terminal flanking domains of glycoprotein Ibalpha. Blood 2001; 98: 652-660.
• 3 Cauwenberghs N, Meiring M, Vauterin S. et al. Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in non-human primates. Arteriosclerosis Thromb Vasc Biol 2000; 20: 1347-1353.
• 4 Wu D, Meiring M, Kotze HF. et al. Inhibition of platelet glycoprotein Ib, glycoprotein IIb/IIIa, or both by monoclonal antibodies prevents arterial thrombosis in baboons. Arteriosclerosis Thromb Vasc Biol 2002; 22: 323-328.
• 5 Vanhoorelbeke K, Ulrichts H, Van De WG. et al. Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Design 2007; 13: 2684-2697.
• 6 Cauwenberghs N, Schlammadinger A, Vauterin S. et al. Fc-receptor dependent platelet aggregation induced by monoclonal antibodies against platelet glyco-protein Ib or von Willebr and factor. Thromb Haemost 2001; 85: 679-685.
• 7 Fontayne A, De Maeyer B, De Maeyer M. et al. Paratope and epitope mapping of the antithrombotic antibody 6B4 in complex with platelet glycoprotein Ib-alpha. J Biol Chem 2007; 282: 23517-23524.
• 8 Huizinga EG, Tsuji S, Romijn RA. et al. Structures of glycoprotein Ibalpha and its complex with von Willebrand factor A1 domain. Science 2002; 297: 1176-1179.
• 9 Uff S, Clemetson JM, Harrison T. et al. Crystal Structure of the Platelet Glycoprotein Ibalpha N-terminal Domain Reveals an Unmasking Mechanism for Receptor Activation. J Biol Chem 2002; 277: 35657-35663.
• 10 Fontayne A, Vanhoorelbeke K, Pareyn I. et al. Rational humanization of the powerful antithrombotic anti-GPIba antibody: 6B4. Thromb Haemost 2006; 96: 671-684.
• 11 Yao SK, McNatt J, Cui K. et al. Combined ADP and thromboxane A2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation 1993; 88: 2888-2893.
• 12 Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997; 349: 1269-1276.
• 13 Cooke GE, Goldschmidt-Clermont PJ. The safety and efficacy of aspirin and clopidogrel as a combination treatment in patients with coronary heart disease. Expert Opin Drug Saf 2006; 05: 815-826.
• 14 De Meyer SF, Vanhoorelbeke K, Ulrichts H. et al. Development of monoclonal antibodies that inhibit platelet adhesion or aggregation as potential antithrombotic drugs. Cardiovasc Hematol Dis Drug Targets 2006; 06: 191-207.
• 15 Cauwenberghs N, Ajzenberg N, Vauterin S. et al. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin- induced glycoprotein Ib-von Willebrand factor interaction. Haemostasis 2000; 30: 139-148.
• 16 van Zanten GH, Heijnen HFG, Wu YP. et al. A fifty percent reduction of platelet surface glycoprotein Ib does not affect platelet adhesion under flow conditions. Blood 1998; 91: 2353-2359.
• 17 Kageyama S, Matsushita J, Yamamoto H. Effect of a humanized monoclonal antibody to von Willebrand factor in a canine model of coronary arterial thrombosis. Eur J Pharmacol 2002; 443: 143-149.
• 18 Cramer EM, Lu H, Caen JP. et al. Differential redistribution of platelet glycoproteins Ib and IIb-IIIa after plasmin stimulation. Blood 1991; 77: 694-699.
• 19 Gardiner EE, Karunakaran D, Shen Y. et al. Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 2007; 05: 1530-1537.
• 20 Nieswandt B, Schulte V, Bergmeier W. et al. Long-term antithrombotic protection by in vivo depletion of platelet glycoproteinVI in mice. J Exp Med 2001; 193: 459-469.
• 21 Folts JD, Crowell Jr EB, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation 1976; 54: 365-370.
• 22 McGhie AI, McNatt J, Ezov N. et al. Abolition of cyclic flow variations in stenosed, endothelium-injured coronary arteries in nonhuman primates with a peptide fragment (VCL) derived from human plasma von Willebrand factor-glycoprotein Ib binding domain. Circulation 1994; 90: 2976-2981.
• 23 Azzam K, Garfinkel LI, Baldit SC. et al. Anti-thrombotic effect of a recombinant von Willebrand factor, VCL, on nitrogen laser-induced thrombus formation in guinea pig mesenteric arteries. Thromb Haemost 1995; 73: 318-323.
• 24 Kageyama S, Yamamoto H, Nakazawa H. et al. Pharmacokinetics and pharmacodynamics of AJW200, a humanized monoclonal antibody to von Willebrand factor, in monkeys. Arterioscler Thromb Vasc Biol 2002; 22: 187-192.
• 25 Wu D, Vanhoorelbeke K, Cauwenberghs N. et al. Inhibition of the von Willebrand (VWF)-collagen interaction by an antihumanVWF monoclonal antibody results in abolition of in vivo arterial platelet thrombus formation in baboons. Blood 2002; 99: 3623-3628.
• 26 Kageyama S, Yamamoto H, Nakazawa H. et al. Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 2001; 101: 395-404.
• 27 Kleinschnitz C, Pozgajova M, Pham M. et al. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007; 115: 2323-2330.